# To Demonstrate the Relative Bioavailability of Fluoxetine Hydrochloride Capsules, 40 mg

> **NCT00947076** · PHASE1 · COMPLETED · sponsor: **Sandoz** · enrollment: 30 (actual)

## Conditions studied

- Depression

## Interventions

- **DRUG:** Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)
- **DRUG:** Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)

## Key facts

- **NCT ID:** NCT00947076
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-02
- **Primary completion:** 2001-04
- **Final completion:** 2001-04
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00947076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00947076, "To Demonstrate the Relative Bioavailability of Fluoxetine Hydrochloride Capsules, 40 mg". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00947076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*